Electronic audit-trail review in peptide research: what the record can and cannot show

Electronic audit trails answer a narrow but important set of questions: who created or changed a record, when the action occurred, and, when captured, why it occurred. In peptide research, those events may sit behind instrument data, sample records, calculations, or clinical-study documentation. The presence of an audit trail does not make the data reliable by itself. Someone must know when to review it, what patterns matter, and how to document follow-up.

What the guidance supports

FDA guidance on computerized systems used in clinical trials describes secure, computer-generated, time-stamped audit trails for actions that create, modify, or delete electronic records. It also states that changes should not obscure the original information and that audit trails should remain available for review. FDA's electronic-records guidance discusses preserving electronic records and associated metadata in a secure, traceable manner.

The FDA data-integrity guidance for drug CGMP takes a risk-based approach. It ties controls to the risk to patients, processes, and products. That supports a cadence based on the system and record rather than an arbitrary schedule applied to every platform.

A practical cadence model

First, inventory the systems that create or retain regulated or decision-relevant records. Assign an owner, record type, review trigger, routine frequency, reviewer, and escalation path. High-impact records may warrant review with each run, batch, or formal approval. Lower-volume administrative systems may use periodic sampling. A system change, unexpected result, access concern, or investigation can trigger an additional review.

The written procedure should define which events reviewers inspect. Examples include deleted or reprocessed records, changes after approval, repeated failed access, altered timestamps where the system permits them, and activity by unexpected accounts. These examples are prompts for a system owner, not a universal checklist.

Reviewers need access to the native audit-trail view and enough context to understand normal workflow. Exporting a flat report may omit metadata or relationships. The review record should identify the period, system, reviewer, exceptions, and linked investigation or resolution.

Scope and limitations

This article synthesizes public FDA guidance. It is not a legal interpretation, validation protocol, or claim that every cited requirement applies to every peptide research setting. Applicable controls depend on the study, product, system use, predicate rules, contracts, and jurisdiction.

Audit trails show recorded system activity. They may not capture actions outside the system, shared-account behavior, undocumented paper work, or whether a scientific judgment was sound. Organizations should have qualified quality, regulatory, clinical, and information-security personnel define the actual review program.

Sources

• FDA electronic systems and records guidance
• FDA data integrity and drug CGMP guidance
• FDA computerized systems used in clinical trials